サマリー

敗血症診断の世界市場規模は、2021年の503百万米ドルから2026年には年率8.9％で771百万米ドルに達すると予測されています。敗血症の発生率の上昇、外科手術の増加、院内感染の多発、多種多様な敗血症診断装置の利用可能性の増加などにより、需要の拡大が見込まれています。敗血症診断薬業界は、技術、製品、手法、病原体、検査タイプ、エンドユーザー、地域によって区分されています。


"2021年の敗血症診断薬業界において、エンドユーザー別では血液培養セグメントが最大のシェアを占めています。"
敗血症診断薬市場は、エンドユーザーに基づいて、血液培養、イムノアッセイ、分子診断、フローサイトメトリー、マイクロフルイディクス、バイオマーカーに分類されます。血液培養は、敗血症の発生率の増加と、敗血症の診断のための血液培養技術の採用が進んでいることから、市場の最大シェアを占めています。

"2021年の敗血症診断薬市場の製品別シェアは、血液培養液部門が最大となった"
製品別の市場は、血液培養培地、アッセイ＆試薬、機器、ソフトウェアに区分されます。敗血症診断薬業界では、全世界で敗血症の診断・鑑別に血液培養検査が標準的な診断方法として使用されていることから、血液培養培地セグメントが最大のシェアを占めています。

"敗血症診断薬市場において北米が最大のシェアを占めた"
世界市場において、北米が最大のシェアを占め、次いで欧州となりました。これは主に、高度な敗血症診断技術の広範な利用可能性、確立された流通経路、感染症のリスク評価における診断製品の臨床的利点に関する国民の大きな認識によるものである可能性があります。




供給側一次面接の内訳。
- 企業タイプ別。Tier1：25％、Tier2：30％、Tier3：45
- 職位別Cレベル：26％、Dレベル：30％、その他。44%
- 地域別北米：40％、欧州：31％、APAC：20％、中南米：6％、中近東・アフリカ：3

敗血症診断市場の有力企業には、bioMérieux（フランス）、Becton, Dickinson and Company（米国）、Danaher Corporation（米国）、T2 Biosystems（米国）、Luminex（米国）、Roche Diagnostics（スイス）、Thermo Fisher Scientific（米国）、Bruker Corporation（米国）、Abbott Laboratories（米国）、Immunexpress（オーストラリア）、Axis-Shield Diagnostics（英国）、Quidel Corporation（米国）、Siemens Healthineers（ドイツ）、EKF Diagnostics（英国）、Seegene Inc.等が挙げられます。,(韓国）、Boditech Med（韓国）、Alifax S.r.l.（イタリア）、AdvanDx（米国）、（米国）、Immunexpress（オーストラリア）、Axis-Shield Diagnostics（イギリス）。

調査範囲
本レポートでは、敗血症診断薬市場を技術、製品、手法、病原体、検査タイプ、エンドユーザー、地域に基づいて調査しています。市場成長に影響を与える重要な要因（ドライバーや阻害要因など）を調査しています。また、ステークホルダーにとっての市場の機会や課題についても分析しています。市場リーダーについては、その成長動向、展望、市場全体への貢献度に関して、競争環境の詳細を提供しています。5つの主要地域とそれぞれの主要国に関して、市場セグメントの売上を予測しています。

レポート購入の主なメリット
本レポートでは、業界動向、トッププレイヤーの市場シェア、企業プロフィールなど、様々なレベルの分析に焦点を当て、これらを総合して基本的な見解を示しています。また、敗血症診断市場の競争環境、ユーザーの新興セグメント、高成長地域とその推進要因、阻害要因、課題、機会についても分析しています。本レポートは、既存企業だけでなく新規参入企業や中小企業にとっても、市場の動向を把握し、より大きな市場シェアを獲得するために役立つものです。

ページTOPに戻る

目次

1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 31
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.3.2 YEARS CONSIDERED FOR THE STUDY 33
1.4 CURRENCY USED FOR THE STUDY 33
1.5 MAJOR MARKET STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA SOURCES 36
2.1.1.1 Indicative list of secondary sources 37
2.1.2 PRIMARY DATA SOURCES 37
FIGURE 2 BREAKDOWN OF PRIMARIES: SEPSIS DIAGNOSTICS MARKET 38
2.2 MARKET ESTIMATION METHODOLOGY 38
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 39
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 39
2.2.1.1 Procedure-based market estimation 39
FIGURE 4 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON PROCEDURE METHODOLOGY 40
FIGURE 5 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON REVENUE MAPPING METHODOLOGY 41
2.2.2 PRIMARY RESEARCH VALIDATION 41
2.3 DATA TRIANGULATION 42
FIGURE 6 DATA TRIANGULATION METHODOLOGY 42
2.4 RESEARCH ASSUMPTIONS 43
2.5 RESEARCH LIMITATIONS 43
3 EXECUTIVE SUMMARY 44
FIGURE 7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION) 44
FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 45
FIGURE 9 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2021 VS. 2026 (USD MILLION) 45
FIGURE 10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2021 VS. 2026 (USD MILLION) 46
FIGURE 11 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN,
2021 VS. 2026 (USD MILLION) 47
FIGURE 12 SEPSIS DIAGNOSTICS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 47
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE SEPSIS DIAGNOSTICS MARKET 48
4 PREMIUM INSIGHTS 49
4.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW 49
FIGURE 14 THE RISING INCIDENCE OF SEPSIS AND THE RISING NUMBER OF HOSPITAL-ACQUIRED INFECTIONS ARE KEY FACTORS DRIVING THE MARKET GROWTH 49
4.2 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 50
FIGURE 15 MOLECULAR DIAGNOSTICS TO REGISTER THE HIGHEST GROWTH IN THE SEPSIS DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 50
4.3 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2021 VS. 2026 (USD MILLION) 51
FIGURE 16 CONVENTIONAL DIAGNOSTICS IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE SEPSIS DIAGNOSTICS MARKET, BY METHOD, DURING THE FORECAST PERIOD 51
4.4 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY (2021) 52
FIGURE 17 BLOOD CULTURE MEDIA SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE SEPSIS DIAGNOSTICS MARKET FOR APAC 52
4.5 GEOGRAPHIC SNAPSHOT OF THE SEPSIS DIAGNOSTICS MARKET 53
FIGURE 18 APAC MARKET TO WITNESS THE HIGHEST GROWTH DURING
THE FORECAST PERIOD (2021–2026) 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.2.1 DRIVERS 55
5.2.1.1 High incidence of sepsis 55
5.2.1.2 Rising incidence of hospital-acquired infections 56
5.2.1.3 Growing funding for sepsis-related research 56
5.2.2 RESTRAINTS 57
5.2.2.1 High cost of automated diagnostic devices 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis 57
5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis 57
5.2.3.3 Growth opportunities in emerging economies 58
5.2.4 CHALLENGES 58
5.2.4.1 Lack of awareness and limited protocols for sepsis diagnosis 58
5.2.4.2 Shortage of skilled healthcare professionals 59
 
5.3 REGULATORY LANDSCAPE 59
5.3.1 NORTH AMERICA 59
5.3.1.1 US 59
5.3.1.2 Canada 59
5.3.2 EUROPE 60
5.3.3 ASIA PACIFIC 60
5.3.3.1 China 60
5.3.3.2 Japan 60
5.3.3.3 India 60
5.3.4 LATIN AMERICA 61
5.4 PATENT ANALYSIS 61
FIGURE 20 TOP 10 PATENT APPLICANTS FOR SEPSIS DIAGNOSTICS
(JANUARY 2011 TO DECEMBER 2021) 61
FIGURE 21 NUMBER OF GRANTED PATENT AND PATENT APPLICATIONS FILED BY APPLICATIONS (JANUARY 2011 TO DECEMBER 2021) 62
FIGURE 22 PATENT DOCUMENTS FOR SEPSIS DIAGNOSTICS, BY LEGAL STATUS (JANUARY 2011 TO DECEMBER 2021) 62
FIGURE 23 REGIONAL ANALYSIS OF PATENTS GRANTED FOR SEPSIS DIAGNOSTICS (JANUARY 2011 TO DECEMBER 2021) 63
5.5 COVID-19 IMPACT ON THE SEPSIS DIAGNOSTICS MARKET 63
5.6 VALUE CHAIN ANALYSIS 64
FIGURE 24 VALUE CHAIN OF THE SEPSIS DIAGNOSTICS MARKET 64
5.7 PRICING TREND ANALYSIS 65
TABLE 1 AVERAGE PRICE OF SEPSIS DIAGNOSTICS BLOOD CULTURE MEDIA, ASSAYS & REAGENT KITS AND EQUIPMENT, BY COUNTRY, 2020 (USD) 65
5.8 REIMBURSEMENT SCENARIO 65
TABLE 2 MS DRG PAYMENT CALCULATED FOR NATIONAL PROVIDERS 66
5.9 PORTER’S FIVE FORCES ANALYSIS 66
TABLE 3 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 66
5.9.1 THREAT OF NEW ENTRANTS 67
FIGURE 25 THREAT OF NEW ENTRANTS 67
5.9.2 THREAT OF SUBSTITUTES 68
FIGURE 26 THREAT OF SUBSTITUTES 68
5.9.3 BARGAINING POWER OF SUPPLIERS 68
FIGURE 27 BARGAINING POWER OF SUPPLIERS 68
5.9.4 BARGAINING POWER OF BUYERS 69
FIGURE 28 BARGAINING POWER OF BUYERS 69
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 69
FIGURE 29 INTENSITY OF COMPETITIVE RIVALRY 70
5.10 ECOSYSTEM COVERAGE 70
 
6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY 71
6.1 INTRODUCTION 72
TABLE 4 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 72
6.2 BLOOD CULTURE (MICROBIOLOGY TESTING) 72
6.2.1 BLOOD CULTURE IS THE MOST COMMONLY ADOPTED TECHNOLOGY FOR SEPSIS DIAGNOSTICS 72
TABLE 5 BLOOD CULTURE MARKET, BY REGION, 2019–2026 (USD MILLION) 73
TABLE 6 BLOOD CULTURE MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 73
TABLE 7 BLOOD CULTURE MARKET, BY METHOD, 2019–2026 (USD MILLION) 73
TABLE 8 BLOOD CULTURE MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION) 74
TABLE 9 BLOOD CULTURE MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 74
TABLE 10 BLOOD CULTURE MARKET, BY END USER, 2019–2026(USD MILLION) 74
6.3 IMMUNOASSAYS 75
6.3.1 PRODUCT DEVELOPMENT BY MAJOR PLAYERS HAS ENSURED
THE DEMAND FOR IMMUNOASSAYS 75
TABLE 11 IMMUNOASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION) 75
TABLE 12 IMMUNOASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 76
TABLE 13 IMMUNOASSAYS MARKET, BY METHOD, 2019–2026 (USD MILLION) 76
TABLE 14 IMMUNOASSAYS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION) 76
TABLE 15 IMMUNOASSAYS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 77
TABLE 16 IMMUNOASSAYS DIAGNOSTICS MARKET, BY END USER,
2019–2026(USD MILLION) 77
6.4 MOLECULAR DIAGNOSTICS 77
TABLE 17 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026(USD MILLION) 78
TABLE 18 MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 78
TABLE 19 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 78
TABLE 20 MOLECULAR DIAGNOSTICS MARKET, BY METHOD,
2019–2026 (USD MILLION) 79
TABLE 21 MOLECULAR DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION) 79
TABLE 22 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 79
TABLE 23 MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026(USD MILLION) 80
6.4.1 POLYMERASE CHAIN REACTION (PCR) 80
6.4.1.1 Quick turnaround time, coupled with technological advancements to increase the adoption of PCR for sepsis diagnosis 80
TABLE 24 PCR MARKET, BY REGION, 2019–2026 (USD MILLION) 80
TABLE 25 PCR MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 81
TABLE 26 PCR MARKET, BY METHOD, 2019–2026 (USD MILLION) 81
TABLE 27 PCR MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION) 81
TABLE 28 PCR MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 82
TABLE 29 PCR MARKET, BY END USER, 2019–2026(USD MILLION) 82
6.4.2 DNA MICROARRAYS 82
6.4.2.1 Simultaneous analysis capabilities & accuracy have driven
the use of microarrays 82
TABLE 30 DNA MICROARRAYS MARKET, BY REGION, 2019–2026 (USD MILLION) 83
TABLE 31 DNA MICROARRAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 83
TABLE 32 DNA MICROARRAYS MARKET, BY METHOD, 2019–2026 (USD MILLION) 83
TABLE 33 DNA MICROARRAYS MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION) 84
TABLE 34 DNA MICROARRAYS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 84
TABLE 35 DNA MICROARRAYS MARKET, BY END USER, 2019–2026(USD MILLION) 84
6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION (PNA-FISH) 85
6.4.3.1 PNA-FISH kits allow for the rapid diagnosis
of bloodstream infections (BSIs) 85
TABLE 36 PNA-FISH MARKET, BY REGION, 2019–2026 (USD MILLION) 85
TABLE 37 PNA-FISH MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 85
TABLE 38 PNA-FISH MARKET, BY METHOD, 2019–2026 (USD MILLION) 86
TABLE 39 PNA-FISH MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION) 86
TABLE 40 PNA-FISH MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 86
TABLE 41 PNA-FISH MARKET, BY END USER, 2019–2026(USD MILLION) 87
6.4.4 DNA SEQUENCING 87
6.4.4.1 DNA Sequencing shortens the time for sepsis diagnosis,
and NGS has applications in COVID-19 diagnosis 87
TABLE 42 DNA SEQUENCING, BY REGION, 2019–2026 (USD MILLION) 88
TABLE 43 DNA SEQUENCING MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 88
TABLE 44 DNA SEQUENCING MARKET, BY METHOD, 2019–2026 (USD MILLION) 88
TABLE 45 DNA SEQUENCING MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION) 89
TABLE 46 DNA SEQUENCING MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 89
TABLE 47 DNA SEQUENCING MARKET, BY END USER, 2019–2026(USD MILLION) 89
6.4.5 SYNDROMIC PANEL-BASED TESTING 90
6.4.5.1 High costs and accuracy errors limit the adoption
of syndromic-panel-based tests 90
TABLE 48 SYNDROMIC PANEL-BASED TESTING MARKET, BY REGION,
2019–2026 (USD MILLION) 90
TABLE 49 SYNDROMIC PANEL-BASED TESTING MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 90
TABLE 50 SYNDROMIC PANEL-BASED TESTING MARKET, BY METHOD,
2019–2026 (USD MILLION) 91
TABLE 51 SYNDROMIC PANEL-BASED TESTING MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION) 91
TABLE 52 SYNDROMIC PANEL-BASED TESTING MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 91
TABLE 53 SYNDROMIC PANEL-BASED TESTING MARKET, BY END USER,
2019–2026(USD MILLION) 92
6.5 FLOW CYTOMETRY 92
6.5.1 LACK OF STANDARDIZED PROTOCOLS IS A KEY
RESTRAINT IN FLOW CYTOMETRY 92
TABLE 54 FLOW CYTOMETRY MARKET, BY REGION, 2019–2026 (USD MILLION) 92
TABLE 55 FLOW CYTOMETRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 93
TABLE 56 FLOW CYTOMETRY MARKET, BY METHOD, 2019–2026 (USD MILLION) 93
TABLE 57 FLOW CYTOMETRY MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION) 93
TABLE 58 FLOW CYTOMETRY MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 94
TABLE 59 FLOW CYTOMETRY MARKET, BY END USER, 2019–2026(USD MILLION) 94
6.6 MICROFLUIDICS 94
6.6.1 RISING ADOPTION OF ADVANCED & RAPID TESTING TO DRIVE THE GROWTH OF THE MICROFLUIDICS SEGMENT 94
TABLE 60 MICROFLUIDICS MARKET, BY REGION, 2019–2026 (USD MILLION) 95
TABLE 61 MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 95
TABLE 62 MICROFLUIDICS MARKET, BY METHOD, 2019–2026 (USD MILLION) 95
TABLE 63 MICROFLUIDICS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION) 96
TABLE 64 MICROFLUIDICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 96
TABLE 65 MICROFLUIDICS MARKET, BY END USER, 2019–2026(USD MILLION) 96
6.7 BIOMARKERS 97
6.7.1 RESEARCH & DEVELOPMENT FOR THE DISCOVERY OF NOVEL BIOMARKERS TO DRIVE THE GROWTH OF THIS SEGMENT 97
TABLE 66 BIOMARKERS MARKET, BY REGION, 2019–2026 (USD MILLION) 97
TABLE 67 BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 98
TABLE 68 BIOMARKERS MARKET, BY METHOD, 2019–2026 (USD MILLION) 98
TABLE 69 BIOMARKERS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION) 98
TABLE 70 BIOMARKERS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 99
TABLE 71 BIOMARKERS MARKET, BY END USER, 2019–2026(USD MILLION) 99
7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT 100
7.1 INTRODUCTION 101
TABLE 72 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 101
7.2 BLOOD CULTURE MEDIA 101
7.2.1 RISE IN BLOODSTREAM INFECTIONS TO DRIVE THE GROWTH OF BLOOD CULTURE MEDIA IN SEPSIS DIAGNOSIS 101
FIGURE 30 INCIDENCE OF BLOODSTREAM INFECTIONS BY AGE AND SEX, WESTERN INTERIOR OF BRITISH COLUMBIA AND CANADA, 2010–2019 102
TABLE 73 BLOOD CULTURE MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION) 102
7.3 ASSAYS & REAGENT KITS 103
7.3.1 ASSAYS BETTER ENABLE THE ANALYSIS OF PATIENT
SAMPLES FOR DISEASE DIAGNOSIS 103
TABLE 74 ASSAYS & REAGENT KITS MARKET, BY REGION, 2019–2026 (USD MILLION) 103
 
7.4 INSTRUMENTS 104
7.4.1 TRADITIONAL DIAGNOSTIC INSTRUMENTS ARE GRADUALLY BEING REPLACED BY AUTOMATED INSTRUMENTS 104
TABLE 75 INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION) 104
7.5 SOFTWARE 105
7.5.1 RISING USE OF AUTOMATED INSTRUMENTS TO ENSURE THE GROWING DEMAND FOR SOFTWARE 105
TABLE 76 SOFTWARE MARKET, BY REGION, 2019–2026 (USD MILLION) 105
8 SEPSIS DIAGNOSTICS MARKET, BY METHOD 106
8.1 INTRODUCTION 107
TABLE 77 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019–2026 (USD MILLION) 107
8.1.1 CONVENTIONAL DIAGNOSTICS 107
8.1.1.1 Higher adoption of conventional diagnostics owing to blood culture testing to drive the growth of this segment 107
TABLE 78 CONVENTIONAL DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 108
8.1.2 AUTOMATED DIAGNOSTICS 108
8.1.2.1 Accuracy & quick turnaround times to drive the adoption of automated diagnostics among medical professionals 108
TABLE 79 AUTOMATED DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 109
9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE 110
9.1 INTRODUCTION 111
TABLE 80 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION) 111
9.2 BACTERIAL SEPSIS 111
TABLE 81 BACTERIAL SEPSIS MARKET, BY TYPE, 2019–2026 (USD MILLION) 111
9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS 112
9.2.1.1 Increased proportion of sepsis infection caused by gram-negative bacteria 112
TABLE 82 GRAM-NEGATIVE BACTERIAL CAUSES IN ADULT SEPSIS 112
TABLE 83 GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION,
2019–2026 (USD MILLION) 113
9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS 113
9.2.2.1 Cases of sepsis caused by gram-positive bacteria have
risen in recent years 113
TABLE 84 GRAM-POSITIVE BACTERIAL CAUSES IN ADULT SEPSIS 113
TABLE 85 GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION,
2019–2026 (USD MILLION) 114
9.3 FUNGAL SEPSIS 114
9.3.1 THE RISING INCIDENCE OF FUNGAL HAIS HAS INCREASED THE RISK OF SEPSIS DEVELOPMENT 114
TABLE 86 FUNGAL SEPSIS MARKET, BY REGION, 2019–2026 (USD MILLION) 115
 
9.4 VIRAL SEPSIS 115
9.4.1 VIRAL PATHOGEN A NEW CAUSATIVE AGENT OF SEPSIS 115
TABLE 87 VIRAL SEPSIS MARKET, BY REGION, 2019–2026 (USD MILLION) 116
9.5 OTHER PATHOGENS 116
TABLE 88 OTHER PATHOGENS MARKET, BY REGION, 2019–2026 (USD MILLION) 116
10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE 117
10.1 INTRODUCTION 118
TABLE 89 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 118
10.2 LABORATORY TESTS 118
10.2.1 LABORATORY TESTS ARE THE MOST COMMON AND
PREFERRED MODE OF TESTING 118
TABLE 90 LABORATORY TEST MARKET FOR SEPSIS DIAGNOSTICS, BY REGION,
2019–2026(USD MILLION) 119
10.3 POINT-OF-CARE TESTS 119
10.3.1 RAPID POC TESTING DRIVES THE GROWTH OF THIS SEGMENT 119
TABLE 91 POC TESTS MARKET FOR SEPSIS DIAGNOSTICS, NY REGION,
2019–2026(USD MILLION) 120
11 SEPSIS DIAGNOSTICS MARKET, BY END USER 121
11.1 INTRODUCTION 122
TABLE 92 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019–2026(USD MILLION) 122
11.2 HOSPITALS AND SPECIALTY CLINICS 122
11.2.1 INCREASING ADOPTION OF SEPSIS DIAGNOSTIC PRODUCTS BY IN-HOUSE HOSPITAL LABS TO BOOST SEGMENT GROWTH 122
TABLE 93 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS AND SPECILAITY CLINICS,
BY REGION, 2019–2026 (USD MILLION) 123
11.3 PATHOLOGY & REFERENCE LABORATORIES 123
11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABLE AND EFFICIENT DIAGNOSTIC SERVICES 123
TABLE 94 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 2019–2026 (USD MILLION) 124
11.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 124
11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS FOR EARLY SEPSIS DETECTION DRIVES THE GROWTH OF THIS SEGMENT 124
TABLE 95 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2019–2026 (USD MILLION) 125
12 SEPSIS DIAGNOSTICS MARKET, BY REGION 126
12.1 INTRODUCTION 127
12.2 NORTH AMERICA 127
FIGURE 31 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 127
TABLE 96 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 128
TABLE 97 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION) 128
TABLE 98 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 129
TABLE 99 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2019–2026 (USD MILLION) 129
TABLE 100 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION) 129
TABLE 101 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 130
TABLE 102 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2019–2026(USD MILLION) 130
12.2.1 US 130
12.2.1.1 Rising incidence of HIAS in us to accelerate the demand for sepsis diagnosis 130
TABLE 103 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 132
TABLE 104 US: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 132
12.2.2 CANADA 133
12.2.2.1 The growing availability of sepsis diagnostic products is expected to drive market growth in Canada 133
TABLE 105 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 134
TABLE 106 CANADA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 134
12.3 EUROPE 135
TABLE 107 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 135
TABLE 108 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 136
TABLE 109 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 136
TABLE 110 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2019–2026 (USD MILLION) 136
TABLE 111 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION) 137
TABLE 112 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 137
TABLE 113 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2019–2026(USD MILLION) 137
12.3.1 GERMANY 138
12.3.1.1 Growing awareness and the adoption of technologically advanced diagnostics products in Germany to drive the market growth 138
TABLE 114 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 139
TABLE 115 GERMANY: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION) 139
12.3.2 UK 139
12.3.2.1 Government support and rising awareness for the early diagnosis of sepsis are the key factors driving market growth in the UK 139
TABLE 116 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 140
TABLE 117 UK: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 140
12.3.3 FRANCE 141
12.3.3.1 The high incidence of sepsis in France has supported the demand for sepsis diagnostic products 141
TABLE 118 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 141
TABLE 119 FRANCE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 142
12.3.4 ITALY 142
12.3.4.1 Limited growth in the healthcare sector to restrain the market growth for sepsis diagnostics in Italy 142
TABLE 120 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 143
TABLE 121 ITALY: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 143
12.3.5 SPAIN 143
12.3.5.1 Rising awareness for the early diagnosis of sepsis to drive the market growth in Spain 143
TABLE 122 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 144
TABLE 123 SPAIN: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 144
12.3.6 REST OF EUROPE 145
TABLE 124 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 145
TABLE 125 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION) 146
12.4 ASIA PACIFIC 146
TABLE 126 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 146
TABLE 127 ASIA PACIFIC: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION) 147
TABLE 128 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 147
TABLE 129 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2019–2026 (USD MILLION) 147
TABLE 130 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION) 148
TABLE 131 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 148
TABLE 132 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2019–2026(USD MILLION) 148
12.4.1 JAPAN 149
12.4.1.1 Rising incidence of pneumonia and infectious diseases to support the market growth in Japan 149
TABLE 133 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 149
TABLE 134 JAPAN: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 150
12.4.2 CHINA 150
12.4.2.1 Healthcare infrastructure improvements to support the market growth for sepsis diagnostics in China 150
TABLE 135 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 151
TABLE 136 CHINA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 151
12.4.3 INDIA 152
12.4.3.1 Increasing patient population and the rising number of surgical procedures to drive the market growth in India 152
TABLE 137 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 153
TABLE 138 INDIA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 153
12.4.4 AUSTRALIA 153
12.4.4.1 The increasing number of sepsis treatment procedures indicates growth potential for the sepsis diagnostics market in Australia 153
TABLE 139 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 154
TABLE 140 AUSTRALIA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION) 154
12.4.5 SOUTH KOREA 155
12.4.5.1 Rising healthcare spending to support the market
growth in South Korea 155
TABLE 141 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 155
TABLE 142 SOUTH KOREA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION) 156
12.4.6 THE REST OF ASIA PACIFIC (ROAPAC) 156
TABLE 143 ROAPAC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 157
TABLE 144 ROAPAC: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 157
12.5 LATIN AMERICA 157
TABLE 145 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 158
TABLE 146 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION) 158
TABLE 147 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 159
TABLE 148 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2019–2026 (USD MILLION) 159
TABLE 149 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION) 159
TABLE 150 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 160
TABLE 151 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2019–2026(USD MILLION) 160
12.5.1 BRAZIL 160
12.5.1.1 Brazil accounted for the largest share of the LATAM market in 2020 owing to the ongoing investments by manufacturers in the country 160
TABLE 152 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 161
TABLE 153 BRAZIL: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 161
12.5.2 MEXICO 161
12.5.2.1 Rising medical tourism to support the market growth in Mexico 161
TABLE 154 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 162
TABLE 155 MEXICO: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION) 162
12.5.3 THE REST OF LATIN AMERICA (ROLATAM) 163
TABLE 156 ROLATAM: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 163
TABLE 157 ROLATAM: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION) 163
12.6 MIDDLE EAST & AFRICA 164
12.6.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS DRIVES SEPSIS OCCURRENCE IN THE MEA REGION 164
TABLE 158 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 165
TABLE 159 MIDDLE EAST & AFRICA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION) 165
TABLE 160 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 166
TABLE 161 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2019–2026 (USD MILLION) 166
TABLE 162 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION) 166
TABLE 163 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 167
TABLE 164 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019–2026(USD MILLION) 167
13 COMPETITIVE LANDSCAPE 168
13.1 OVERVIEW 168
13.2 KEY PLAYER STRATEGIES 169
13.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 170
13.4 MARKET SHARE ANALYSIS (2020) 170
TABLE 165 SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION 170
13.5 COMPETITIVE LEADERSHIP MAPPING 172
13.5.1 STARS 172
13.5.2 PERVASIVE PLAYERS 172
13.5.3 EMERGING LEADERS 173
13.5.4 PARTICIPANTS 173
FIGURE 33 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020 173
13.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020) 174
13.6.1 PROGRESSIVE COMPANIES 174
13.6.2 STARTING BLOCKS 174
13.6.3 RESPONSIVE COMPANIES 174
13.6.4 DYNAMIC COMPANIES 174
FIGURE 34 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2020 175
13.7 FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE SEPSIS DIAGNOSTICS MARKET 176
TABLE 166 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE SEPSIS DIAGNOSTICS MARKET 176
TABLE 167 PRODUCT FOOTPRINT OF COMPANIES 177
TABLE 168 REGIONAL FOOTPRINT OF COMPANIES 178
13.8 COMPETITIVE SCENARIO 179
13.8.1 SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS 179
TABLE 169 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS, JANUARY 2018–DECEMBER 2021 179
13.8.2 SEPSIS DIAGNOSTICS MARKET: DEALS 179
TABLE 170 KEY DEALS, JANUARY 2018–DECEMBER 2021 179
13.8.3 SEPSIS DIAGNOSTICS MARKET: OTHER DEVELOPMENTS 180
TABLE 171 OTHER KEY DEVELOPMENTS, JANUARY 2018–DECEMBER 2021 180
14 COMPANY PROFILES 181
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1 BIOMÉRIEUX 181
TABLE 172 BIOMÉRIEUX.: BUSINESS OVERVIEW 181
FIGURE 35 BIOMÉRIEUX: COMPANY SNAPSHOT (2020) 182
TABLE 173 BIOMÉRIEUX.: PRODUCT OFFERINGS 183
14.2 BECTON, DICKINSON, AND COMPANY 186
TABLE 174 BECTON, DICKINSON, AND COMPANY: BUSINESS OVERVIEW 186
FIGURE 36 BECTON, DICKINSON, AND COMPANY: COMPANY SNAPSHOT (2020) 187
TABLE 175 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERINGS 188
14.3 DANAHER CORPORATION 190
TABLE 176 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
TABLE 177 DANAHER CORPORATION: PRODUCT OFFERINGS 192
 
14.4 T2 BIOSYSTEMS 194
TABLE 178 T2 BIOSYSTEMS: BUSINESS OVERVIEW 194
FIGURE 38 T2 BIOSYSTEMS: COMPANY SNAPSHOT (2020) 194
TABLE 179 T2 BIOSYSTEMS: PRODUCT OFFERINGS 195
14.5 LUMINEX 197
TABLE 180 LUMINEX: BUSINESS OVERVIEW 197
FIGURE 39 LUMINEX: COMPANY SNAPSHOT (2020) 198
TABLE 181 LUMINEX: PRODUCT OFFERINGS 199
14.6 F. HOFFMANN-LA ROCHE AG 200
TABLE 182 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 200
FIGURE 40 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020) 201
TABLE 183 F. HOFFMANN-LA ROCHE AG: PRODUCT OFFERINGS 201
14.7 THERMO FISHER SCIENTIFIC 203
TABLE 184 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 203
FIGURE 41 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020) 204
TABLE 185 THERMO FISHER SCIENTIFIC: PRODUCT OFFERINGS 205
14.8 BRUKER CORPORATION 206
TABLE 186 BRUKER CORPORATION: BUSINESS OVERVIEW 206
FIGURE 42 BRUKER CORPORATION: COMPANY SNAPSHOT (2020) 207
TABLE 187 BRUKER CORPORATION: PRODUCT OFFERINGS 207
14.9 ABBOTT LABORATORIES 209
TABLE 188 ABBOTT LABORATORIES: BUSINESS OVERVIEW 209
FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 210
TABLE 189 ABBOTT LABORATORIES: PRODUCT OFFERINGS 210
14.10 QUIDEL CORPORATION 211
TABLE 190 QUIDEL CORPORATION: BUSINESS OVERVIEW 211
FIGURE 44 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020) 212
TABLE 191 QUIDEL CORPORATION: PRODUCT OFFERINGS 212
14.11 SIEMENS HEALTHINEERS 213
TABLE 192 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 213
FIGURE 45 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020) 214
TABLE 193 SIEMENS HEALTHINEERS: PRODUCT OFFERINGS 214
14.12 EKF DIAGNOSTICS 216
TABLE 194 EKF DIAGNOSTICS: BUSINESS OVERVIEW 216
FIGURE 46 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2020) 217
TABLE 195 EKF DIAGNOSTICS: PRODUCT OFFERINGS 217
14.13 SYSMEX CORPORATION 219
TABLE 196 SYSMEX CORPORATION: BUSINESS OVERVIEW 219
FIGURE 47 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020) 220
TABLE 197 SYSMEX CORPORATION: PRODUCT OFFERINGS 220
 
14.14 SEEGENE, INC. 222
TABLE 198 SEEGENE, INC.: BUSINESS OVERVIEW 222
TABLE 199 SEEGENE, INC: PRODUCT OFFERINGS 222
14.15 RESPONSE BIOMEDICAL CORP. 223
TABLE 200 RESPONSE BIOMEDICAL CORP.: BUSINESS OVERVIEW 223
TABLE 201 RESPONSE BIOMEDICAL CORP.: PRODUCT OFFERINGS 223
14.16 OTHER COMPANIES 224
14.16.1 ALIFAX S.R.L. 224
14.16.2 BODITECH MED INC. 225
14.16.3 ADVANDX 225
14.16.4 IMMUNEXPRESS INC. 226
14.16.5 AXIS-SHIELD DIAGNOSTICS 227
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX 228
15.1 DISCUSSION GUIDE 228
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 233
15.3 AVAILABLE CUSTOMIZATIONS 235
15.4 RELATED REPORTS 235
15.5 AUTHOR DETAILS 236